Article

Cardiac Complications in Patients with COVID-19:
An Integrative Literature Review

Complicaciones cardíacas en pacientes con covid-19:
revisión integrativa de la literatura

Complicações cardíacas em pacientes com covid-19:
revisão integrativa da literatura

Suellen Rodrigues de Oliveira Maier ¹
João Paulo Ferreira Rodrigues ²
Mayara Rocha Siqueira Sudré ³
Carina Aparecida Marosti Dessotte ⁴

¹ 0000-0002-4677-1674. Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Brazil. [email protected]

² 0000-0002-4986-1130. Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Brazil. [email protected]

³ 0000-0002-9515-5907. Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Brazil. [email protected]

⁴ 0000-0002-5521-8416. Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Brazil. [email protected]

10.5294/aqui.2020.20.4.3

Received: 18/08/2020
Sent to peers: 30/08/2020
Approved by peers: 21/09/2020
Accepted: 25/09/2020

Theme: Evidence-based practice.

Contribution to the subject: The results of this review are relevant, as it is a synthesis of the findings related to the main cardiac complications in patients with COVID-19. The knowledge about the main clinical, laboratory and imaging findings can favor the early recognition of cardiac complications and assist in decision-making and in the establishment of appropriate therapeutic approaches, in order to avoid unfavorable outcomes during treatment. In short, the cardiac complications evidenced can contribute to the implementation of assistance for this disease, which is so emerging and still unknown in the scientific literature.

To reference this article / Para citar este artigo / Para citar este artículo: Maier SRO, Rodrigues JPF, Sudré MRS, Dessotte CAM. Cardiac Complications in Patients with COVID-19: An Integrative Literature Review. Aquichan. 2020;20(4):e2043. DOI: https://doi.org/10.5294/aqui.2020.20.4.3

Introduction

In 2019, more precisely in December, the first cases of the disease caused by the Severe Acute Respiratory Syndrome Coro-navirus 2 (Sars-CoV-2), a new category of coronavirus⁽¹⁾, were disclosed. The first cases occurred in the city of Wuhan, Hubei province, China, and, in less than 30 days, cases were reported in other countries and even on other continents⁽²⁾.

Some authors described that it was a zoonosis, coming from wild animals, more precisely bats, with high pathogenicity in humans, affecting the airways first, causing severe acute respiratory syndrome and, subsequently, affecting other systems⁽³⁾.

The viral disease, called "COVID-19", has an important potential for transmissibility via air and contact. It is a viral pneumonia, which affects the upper and lower airways, causing severe respiratory failure, with the need, in cases of too much effort by the individual, to offer oxygen by positive pressure, through mechanical invasive ventilation, that is, the patient will need uninterrupted care in an intensive care unit. In some cases, the disease causes progressive and rapid deterioration, leading to death⁽²⁾.

In late January 2020, the World Health Organization declared that Sars-CoV-2, or COVID-19, became a public health emergency, that is, a pandemic^{(4, 5)}. Currently, COVID-19 has already affected the population of several countries in different continents, with contamination records higher than those of other diseases transmitted by air, such as, for example, influenza, and high mortality in older adults and in individuals with pre-existing chronic diseases^(6-8).

Due to the emergency, several therapeutic approaches have been adopted and successful ones have been disseminated in several countries. Studies were carried out that sought to approve the efficacy of drugs such as hydroxychloroquine®, alpha-inter-feron® and lopinavir®; however, they were non-randomized and unblinded studies, which negatively interfered with the level of evidence of the publications. There were also some adverse cardiovascular effects, such as, for example, prolongation of the QT interval, arrhythmias and an increased risk of sudden death^(9-11), based on the drug interaction between some drugs of different pharmacological groups.

Respiratory repercussions —fever, cough, pharyngitis, fatigue and complications related to pneumonia and respiratory syndrome— are the first symptoms in individuals considered symptomatic. However, a number of studies have revealed the involvement of other systems, such as the cardiac one, from the onset of tachyarrhythmias and signs of cardiac failure^{(12, 13)}. In other Chinese studies, in addition to the complications described above, ischemic cardiac events, characteristic of acute myocardial infarction in patients with COVID-19^(14-16), were identified.

Obstructive conditions in individuals with previous coronary artery disease (CAD) and other conduction or mechanical disorders have contributed to the worsening of patients who require intensive care. Some authors highlight the presence of comorbidities, such as systemic arterial hypertension (SAH) and/or diabetes mellitus(DM), as risk factors for the development of cardiac complications during care for individuals with COVID-19. The treatment of these chronic diseases with angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers increases the bioavailability of the angiotensin-converting enzyme 2, which is the target molecule of Sars-CoV-2, found in the epithelial pulmonary, intestinal, and renal tissues, as well as in blood vessels^{(17, 18)}.

As it is an emerging disease with a varied pathogenic profile that triggers important systemic repercussions in order to favor the involvement of the heart, it was sought to identify, based on the literature, what the main cardiac complications are in patients with COVID-19 during hospital treatment.

Materials and methods

This is an integrative review, based on articles published from January to May 2020. The phases related to the study method were distributed sequentially: a) identification of the research question; b) establishment of criteria for the inclusion and exclusion of studies found in the literature; c) definition of the information to be extracted from the selected studies in line with the guiding question; d) evaluation of the studies included in the review; e) interpretation of the results found; and f) synthesis of knowledge^(19-21).

The selection phase of the studies took place in the first half of June 2020, by means of an electronic search paired with original articles and case reports, given the pandemic nature of the disease, which answered the research question, by using the Pico⁽²²⁾ (acronym for patient, intervention, control or comparison and outcomes) strategy, according to Table 1, to construct the following question: Is there scientific evidence in the literature about the main cardiac complications in patients with COVID-19 during hospital treatment?

Table 1. Description of the research question with the use of the PICO strategy. Ribeirão Preto, São Paulo, Brazil, 2020

Source: Elaborated by the authors based on research data.

The final sample consisted of articles published in full, from primary studies or case reports in which the main cardiac complications were evident; published in 2020, in Portuguese, English or Spanish. Articles that did not describe the main cardiac complications during the hospitalization period of patients with COVID-19 were excluded.

The electronic databases accessed were Medical Literature Analysis and Retrieval System Online (Medline), via PubMed; Scopus, via Elsevier; Cumulative Index to Nursing and Allied Health Literature (Cinahl), via EBSCO; Latin American and Caribbean Literature on Health Sciences (Literatura Latino-americana e do Caribe em Ciências da Saúde, Lilacs); Spanish Bibliographic Index on Health Sciences (Índice Bibliográfico Español en Ciencias de la Salud, IBECS), Nursing Database (Base de Dados de Enfermagem, BDEnf), via the Virtual Health Library; Web of Science; and Embase. The choice of these databases was justified by the emerging characteristic of the investigated disease, which allowed for the use of controlled and uncontrolled descriptors (keywords) in a combined manner, using the Boolean operators AND and OR, as described in Table 2.

Table 2. Combinations searched in the databases: Medline, Scopus, Cinahl, Lilacs, IBECS, BDEnf, Web of Science and Embase. Ribeirão Preto, São Paulo, Brazil, 2020

Source: Elaborated by the authors based on research data.

The option to use controlled descriptors, in the Medline/ PubMed, Cinahl, Lilacs, Embase, IBECS and BDEnf databases, and uncontrolled descriptors, in Scopus and Web of Science, occurred because the search was supported in eight databases, with the objective of integrating information about the theme under study.

The combinations and data analysis were carried out independently by the researchers, respecting the inclusion and exclusion criteria described above. Then, the reading of the titles was conducted and those that described the cardiac complications were selected. After this process, the articles were inserted in the Mendeley⁽²⁰⁾ reference manager to separate duplicate studies.

After the analysis of the titles, careful readings of the abstracts were carried out and those that approached the central subject matter, proposed by the guiding question, were selected for full-reading. For consolidation, reading and evaluation were performed, and 16 articles were included in the final sample, which showed cardiac complications through the clinical evolution of the investigated patients, results of laboratory tests, and imaging that showed worsening of the clinical condition.

From the selection of articles, the structural consistency was evaluated, using the following instruments: Case Report Guidelines (Care), for case reports, and Strengthening the Reporting of Observational Studies in Epidemiology (Strobe), for observational studies. Such instruments represent international guidelines for the construction of research reports^(23-25).

Care consists of 13 topics: title, keywords, abstract, introduction, information about the patient, clinical aspects, history, diagnosis, treatment/interventions, outcome, discussion, perspective, and patient consent⁽²⁴⁾. On the other hand, Strobe consists of 22 items: title and abstract; introduction, which includes the justification and objectives; method, which shows the type of study, location, participants, variables, quantitative variables, bias, data collection, data analysis and statistical analysis; results, which bring the number of participants, characterization of the participants, main results, outcome, and other analyses; discussions, which contemplate the key results, limitations, interpretation and generalization; finally, other information with emphasis on the funding of the study, if any⁽²⁴⁾.

Due to the fact that the review proposal is related to an emerging disease and little described in the literature until then, it was sought to highlight the structural consistency of each study from the analysis, using the Care and Strobe instruments. All the selected studies covered the description of all items concerning each type of study. The methodological quality assessment of the selected studies was performed by the authors based on the Critical Appraisal Checklist for Systematic Review and Research Synthesis tool of the Joanna Briggs Institute^(25-27).

The extraction of information related to the main cardiac complications occurred after the consolidation of the final sample of articles included in the present review, with information extracted for the characterization of the manuscript (name of the authors, database, year, title and journal) and the presentation itself of the methodological design, the study population, and the main cardiac complications found.

Results

For the description of the search process, the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) flow diagram was used in order to guide the selection of studies⁽²⁶⁾, as shown in Figure 1.

Figure 1. Flow diagram adapted for selection of studies. Ribeirão Preto, São Paulo, Brazil, 2020

Source: Elaborated by the authors based on research data.

A total of 49 articles were selected for reading their titles; of these, 14 were excluded because they were not primary studies or case reports, leaving 35 articles for reading their abstracts, with the exclusion of 19 articles for not describing cardiac complications in patients with COVID-19 during hospital treatment.

After a careful selection, 16 studies made up the final sample of articles, seven of which were published in journals indexed in Scopus, one in Web of Science, one in Embase and seven in Medline, all published in 2020 and in English. The other databases searched did not have studies selected to compose this review.

The selected studies were published in electronic and publicly accessible journals, with seven being published in journals in the cardiovascular area and the others in journals in other areas.

As for the type of study, 14 were observational studies (cohort or cross-sectional) and three were case reports. The sample consisted of 14 studies developed in China, two in Italy, and one in England. Regarding the objectives, four were related to cardiac complications of patients with COVID-19, seven to cardiovascular complications, naming cardiac complications, and the others referred to complications in general, with emphasis on adverse cardiac events during treatment.

Table 3 shows the data related to the selected studies, according to the authors, database, title, journal, study location, objectives, methodological design, and complications.

Table 3. Studies selected to compose the review, according to authors, database, title, journal, methodological design, and cardiac complications. Ribeirão Preto, São Paulo, Brazil

Source: Elaborated by the authors based on research data.

Based on the cardiac complications evidenced by the authors of the selected studies, the discussion was structured with an emphasis on highlighting cardiac impairment during the treatment of inpatients.

Discussions

The limitations of this study can be related to the possibility of some study which did not necessarily have the objective of describing cardiac complications, but found them from the characterization of the investigated patients. Another possible limitation is associated with the number of studies available in the literature, according to the search strategy used, since it is a new and emerging disease, with a pathogenic potential to be known and therapeutics still being implemented in several countries. Despite the limitations described, the present study advances from the summary of the results regarding care for patients with COVID-19 during hospitalization.

According to Table 3, the cardiac complications described by the authors of the selected articles were arrhythmias^{(1, 2, 15, 28, 31, 32)}, changes in the conduction of the electrical impulse generated by the physiological pacemaker of the heart; acute heart injury^{(1, 7, 8, 12, 17, 32)}, myocardial injury⁽²⁾, coronary heart disease^{(14, 31-34)}, obstructive coronary disease^{(15, 16, 28, 30, 31)} and heart failure^{(15, 28, 32)}.

Seeking to conceptually understand the complications highlighted by the authors of the selected studies, it was verified that the expressions "acute cardiac injury", "myocardial injury", "coronary heart disease" and "obstructive coronary disease" are synonymous, as they were acute diseases centered on the obstruction of the coronary arteries, identified from the laboratory findings (elevation of troponin I, myoglobin creatinophosphokinase [CKMB] and creatine kinase [CK]) and the description of signs and symptoms presented by the participants of the studies that composed this review.

Within the sample of selected articles, those that showed the main cardiac complications in hospitalized patients with COVID-19 were included, even considering studies with participants with pre-existing diseases, such as cardiovascular diseases (CVDs), as they tend to increase the risk of developing more severe conditions in patients with COVID-19, mainly due to the onset of obstructive events and the presence of a systemic inflammatory response^{(35, 36)}.

All the selected studies^{(1, 2, 8, 13-17, 28-34)} for the final sample of this review brought coronary obstructive events as the main cardiac complication evidenced during hospitalization of patients with COVID-19. The obstructive events predominantly represented by acute myocardial infarction are possibly the result of an increased myocardial workload during infections, which cause myocardial injuries^{(37, 38-40)}. In addition, Sars-CoV-2 has been shown to trigger an exaggerated systemic inflammatory response, which, in addition to acute lung injury and acute respiratory distress syndrome, can lead to multiple cardiovascular complications^{(32, 34)}, unstable angina, tachycardia, heart failure, stroke, cardiogenic shock and even cardiopulmonary arrest^{(37, 39)}.

Patients hospitalized with COVID-19 tend to have high serum levels of CK and lactate dehydrogenase. Evidence of myocardial injury, such as increased levels of high cardiac troponin I (cTnI) (> 28 pg/mL), can contribute to the emergence of obstructive events throughout treatment⁽⁴¹⁾. Elevation of biomarkers (troponin I and CKMB), as well as electrocardiographic and echocardiographic changes were observed, revealing a condition of coronary obstruction during hospitalization^{(38, 39)}.

Obstructive injury is caused by the rupture of the plaque or thrombus in the vessel walls, by the proliferation of cytokines, by the reduction of oxygen in the heart muscle, by coronary spasm, by microthrombi or by direct endothelial or vascular injury^{(7, 8, 12, 17, 32, 33, 34, 38, 42, 43)}. Such situations described lead to an obstructive condition, reflected by changes in the cardiac biomarkers and electrocardiographic changes, especially the elevation of the ST segment.

Most of the studies revealed the relationship between laboratory and imaging findings by electrocardiographic examination in patients with comorbidities^{(38, 44, 45)}. The increase in troponin I and CKMB, combined with depression of the ST segment and/or inverted T wave at electrocardiographic examination, increased the risk of death, when combined with systemic arterial hypertension in patients with DM^{(17, 29)}.

The progressive increase in the biomarkers, in addition to indicating coronary obstructive events, can signal the development of systemic complications, such as disseminated intravascular coagulation^{(45, 46)}. This finding considerably raises the mortality rates due to COVID-19^{(8, 12)}, especially in patients with a previous history of SAH, DM, dyslipidemia and/or CAD^{(16, 33, 34, 38)}. From this perspective, it can be said that CVDs are considered important risk factors for the occurrence of cardiac complications during hospitalization, increasing the potential for severity and deaths, especially in aged patients^{(15, 29, 30, 31, 32, 33, 38)}.

In this perspective, the importance of monitoring cardiac biomarkers throughout hospitalization was perceived in order to anticipate cardiac complications, especially in patients with COVID-19 who have previous comorbidities.

Arrhythmias were highlighted in six^{(1, 2, 15, 28, 31, 32)} of the 16 articles included in the final sample of this review; however, only one⁽¹⁵⁾ of them highlighted heart rate. Atrial fibrillation was highlighted as the most common cardiac complication, due to changes in the electrocardiographic tracing, in addition to increased serum levels of hypersensitive cTnI, in patients with COVID-19 admitted to intensive care units⁽¹⁵⁾. In the other articles^{(1, 2, 28, 31, 32)}, the electrocardiographic changes which occurred during hospitalizations of patients with COVID-19 were not described; however, the authors pointed out that arrhythmic conditions can increase the severity of the COVID-19 patients' clinical conditions, due to the presentation of severe cardiac rhythms that evolve to cardiopulmonary arrest, especially in patients with cardiovascular comorbidities identified on admission to the hospital unit.

The Centers for Disease Control and Prevention conducted a survey with 72 patients admitted to a North American medical center, of whom 43 had CVDs, six presented cardiac complications, such as supraventricular tachycardia, atrial fibrillation, atrial flutter or complete atrial ventricular block⁽³⁵⁾. Thus, it was perceived that the arrhythmic conditions need to be identified early so that therapeutic approaches can be taken, with the aim of restoring sinus rhythm.

Heart failure was evidenced in three of the 16 studies included in the final sample of this review. All the articles were developed with adult and aged patients diagnosed with COVID-19, with pre-existing CVDs; however, the development of heart failure was predominantly related to the advanced age profile of the patients under study^{(15, 28, 32)}. It was also verified that the left ventricular ejection fraction of less than 40%, at echocardiographic examination in cases of heart failure, combined with elevated serum troponin I and elevated ST segment at electrocardiographic examination, favor the worsening of COVID-19 patients' prognoses^{(36, 38-40)}.

Infection with Sars-CoV-2 is a mild disease in most people, although a small portion of patients affected by the virus has developed severe respiratory failure characterized by a hyperinflammatory syndrome. Dysfunction of the vascular endothelial cell promoted by viral infection, combined with myocardial depression associated with inflammation, stress cardiomyopathy and/or the host's response can cause or worsen heart failure, demand-related ischemia and arrhythmias⁽³²⁾.

Many discussions have occurred about cardiac complications, diagnosed based on the existence of the arrhythmic conditions identified through electrocardiographic tracings and obstructive events in coronary arteries, verified by electrocardiographic and echocardiographic changes, and by the measurement of cardiac biomarkers^(47-49). From the synthesis of the findings in the texts, it was perceived that cardiac complications can occur at different periods of hospitalization^(40-52) and that the presence of comorbidities^{(38, 49)} can promote worsening of the clinical condition of patients with COVID-19.

In summary, the studies that comprised this review allowed highlighting the importance of the cardiac monitoring of patients undergoing COVID-19 treatment, with the aim of intervening early in the reversal of arrhythmic conditions and verifying electrocardiographic findings corresponding to obstructive myocardial injury and heart failure. Some studies highlighted the importance of monitoring cardiac biomarkers in order to make increasingly anticipate the therapeutic approaches.

The study limitation was the number of articles on the subject matter that accurately revealed cardiac complications in patients with COVID-19 during hospitalization, through primary studies and with methodological consistency. Until June 2020, there are many studies underway that will allow greater knowledge about the disease and its complications.

Conclusions

The cardiac complications that most emerged were coronary obstructive events, arrhythmic conditions, and heart failure. It was perceived that such complications can be related to the previous existence of CVDs, verified on admission to the hospital unit, predominantly in patients over the age of 60, who have contracted COVID-19.

Knowledge about cardiac complications during the treatment of patients with COVID-19 has begun to emerge, since it can contribute to the adoption of more efficient care protocols in order to prevent such complications, which leads to favorable outcomes, mainly related to patients with CVDs.

Conflict of interest: None declared.

References

1. Lei S, Jiang F, Sua W, Chend C, Chene J, Meif W et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. E Clinical Medicine. 2020;21:e100331. Available from: https://doi.org/10.1016/j.eclinm.2020.100331

2. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;27:e201017. Available from: https://doi.org/10.1001/jamacardio.2020.1017

3. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17:181-92. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097006/

4. World Health Organization. Pneumonia of unknown cause-China. 2020. Available from: https://www.who.int/csr/don/05-april-2020-pneumonia-of-unkown-cause-china/en/

5. World Health Organization. Novel coronavirus-China. 2020. Available from: https://www.who.int/csr/don/12-april-2020-novel-coronavirus-china/en/

6. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):e135. Available from: https://doi.org/10.3390/v12020135

7. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199-207. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121484/

8. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(1):507-13. DOI: https://doi.org/10.1016/S0140-6736(20)30211-7

9. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. Int J Antimicrob Agents. 2020;e105949 Available from: https://doi.org/10.1016/j.ijantimicag.2020.105949

10. Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease. 2020;35:e101738. Available from: https://doi.org/10.1016/j.tmaid.2020.101738

11. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation. 2020;141:e906-7. DOI: https://doi.org/10.1161/CIRCULATIONA-HA.120.047521

12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159299/

13. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D et al. Cardiac involvement in a patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819-24. DOI: https://doi.org/10.1001/jamacardio.2020.1096

14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet. 2020;395:1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang Z et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA Cardiol. 2020;323(11):10619. DOI: https://doi.org/10.1001/jama.2020.1585

16. Zeng J, Liu Y, Yuan J, Wang F, Wu W, Li J et al. First case of COVID-19 complicated with fulminant myocarditis: A case report and insights. Infection. 2020;10(ahead of print):1-5. DOI: https://doi.org/10.1007/s15010-020-01424-5

17. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950. DOI: https://doi.org/10.1001/jamacardio.2020.0950

18. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. DOI: https://doi.org/10.1016/S2213-2600(20)30116-8

19. Mendes KDS, Silveira RCCP, Galvão CM. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto Contexto Enferm. 2008;17(4):758-64. DOI: https://dx.doi.org/10.1590/S0104-07072008000400018

20. Mendes KDS, Silveira RCCP, Galvão CM. Uso de gerenciador de referências bibliográficas na seleção dos estudos primários em revisão integrativa. Texto Contexto Enferm. 2019; 28:e20170204. DOI: https://dx.doi.org/10.1590/1980-265X-TCE-2017-0204

21. Melnyk BM, Fineout-Overholt E. Making the case for evidence based practice. Melnyk BM, Fineout-Overholt E, organizadores. Evidence based practice in nursing & health care. A guide to best practice. Philadelphia (US): Lippincot Williams & Wilkins; 2005. p. 3-24.

22. Santos CMC, Pimenta CAM, Nobre MRC. The PICO strategy for the research question construction and evidence search. Rev Latino-am Enfermagem. 2007;15(3):508-11. Available from: http://www.scielo.br/pdf/rlae/v15n3/v15n3a23.pdf

23. Simera I, Altman DG, Moher D, Schulz KF, Hoey J. Guidelines for Reporting Health Research: The EQUATOR Network's Survey of Guideline Authors. PLoS Med. 2008;5(6): e139. DOI: https://doi.org/10.1371/journal.pmed.0050139

24. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. STROBE Initiative. J Clin Epidemiol. 2008;61(4):344-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18313558

25. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: Consensus-based clinical case reporting guideline development. Headache. 2013;53(10):1541-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24266334

26. Moher D, Shamseer L, Clarke M, Ghersi D, Liberrati A, Petticrew M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Bio Med Central. 2015;4(1):1-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25554246

27. Aromataris E, Munn Z. Chapter 1: JBI Systematic Reviews. In: Aromataris E, Munn Z, editores. JBI Reviewer's Manual. JBI; 2017. DOI: https://doi.org/10.46658/JBIRM-17-01

28. Inciardi RM, Adamo M, Lupi L, Cani DS, Pasquale MD, Tomasoni D et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European Heart Journal. 2020;41:1821-9. DOI: https://doi.org/10.1093/eurheartj/ehaa388

29. Li M, Dong Y, Wang H, Guo W, Zhou H, Zhang Z et al. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutrition, Metabolism & Cardiovascular Diseases. 2020;30(7):1061-7. DOI: https://doi.org/10.1016/j.numecd.2020.04.013

30. Xiong F, Tang H, Liu L, Tu C, Tian JB, Lei CT et al. Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China. JASN. 2020; ASN.2020030354. DOI: https://doi.org/10.1681/ASN.2020030354

31. Zhang J, Lu S, Wang X, Jia X, Li J, Lei H et al. Do underlying cardiovascular diseases have any impact on hospitalised patients with COVID-19? Heart. 2020;106:1119-21. DOI: http://dx.doi.org/10.1136/heartjnl-2020-317110

32. Zhen Y, Xua H, Yanga M, Zenga Y, Chena H, Liu R et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. Journal of Clinical Virology. 2020;127:104366. DOI: https://doi.org/10.1016/j.jcv.2020.104366

33. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. Journal of Medical Virology. 2020;92(7):797-806. Available from: https://pubmed.ncbi.nlm.nih.gov/32198776/

34. Rothstein ES, Welch TD, Andrus BW, Jayne JE. Management of a patient presenting with anterior STEMI with concomitant COVID-19 infection early in the course of the U.S. pandemic. Catheter Cardiovasc Interv. 2020;1-6. DOI: https://doi.org/10.1002/ccd.28967

35. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system. JAMA Cardiol. 2020;5(7):831-40. DOI: https://doi:10.1001/jamacardio.2020.1286

36. Ferguson J, Rosser JI, Quintero O, Scott J, Subramanian A, Gumma M et al. Characteristics and outcomes of coro-navirus disease patients under nonsurge conditions, northern California, USA, March-April 2020. Emerg Infect Dis. 2020;26(8):1679-85. DOI: https://doi.org/10.3201/eid2608.201776

37. Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020;5(7):751-3. DOI: http://doi.org/10.1001/jamacardio.2020.1105

38. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020,27(7):E1-9. DOI: https://doi.org/10.1001/jamacardio.2020.3557

39. Ferrari F. COVID-19: dados atualizados e sua relação com o sistema cardiovascular. Arq Bras Cardiol. 2020;114(5):823-6. DOI: https://doi.org/10.36660/abc.20200215

40. Askin L, Tanriverdi O, Askin H S. O efeito da doença de coronavirus 2019 nas doenças cardiovasculares. Arq Bras Cardiol. 2020;114(5):817-22. DOI: https://doi.org/10.36660/abc.20200273

41. Pacileo M, Giallauria F, Savarese C, Cirillo T, Crescibene F, Lorenzo AD et al. The role of echocardiography in SARS-CoV-2 pandemic: A compromise among appropriateness, safety and clinical impact. Monaldi Archives for Chest Disease. 2020;90:1358. Available from: https://www.monaldi-archives.org/index.php/macd/article/view/1358/1028

42. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63(3):390-1. DOI: https://doi.org/10.1016/j.pcad.2020.03.001

43. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B et al. ST-Segment elevation in patients with Covid-19 — A case series. N Engl J Med. 2020;382:2478-80. DOI: https://doi.org/10.1056/NEJMc2009020

44. Wei-jie G, Zheng-yi N, Yu H, Wen-hua L, Chun-quan O, Jian-xing H et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. Available from: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2002032

45. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-9. DOI: https://doi.org/10.1111/jth.14817

46. Liu Z, Xue XB, Zhi XZ. The epidemiological characteristics of an outbreak of 2019 novel Coronavirus Diseases (CO-VID-19) in China. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. 2020;41(2):145-51. Available from: https://pubmed.ncbi.nlm.nih.gov/32064853/

47. Strabelli TMV, Uip DE. Covid-19 e o coração. Arq Bras Cardiol. 2020; 114(4):598-600. DOI: http://dx.doi.org/10.36660/abc.20200209

48. Wang T, Du Z, Zhu F, Cao Z, An Z, Gao Y et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52. DOI: https://doi.org/10.1016/S0140-6736(20)30558-4

49. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diab Res Care. 2020;8:e001343. Available from: https://drc.bmj.com/content/8/1/e001343

50. Sama IE, Ravena A, Santema BT, Goor HV, Maaten JM, Cleland JGF et al. Circulating plasma concentrations of an-giotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. European Heart Journal. 2020;41:1810-7. Available from: https://academic.oup.com/eurheartj/arti-cle/41/19/1810/5834647

51. Gemes K, Talback M, Modig K, Ahlbom A, Berglund A, Feychting M et al. Burden and prevalence of prognostic factors for severe COVID-19 in Sweden. European Journal of Epidemiology. 2020; 35:401-9. DOI: https://doi.org/10.1007/s10654-020-00646-z

52. Abajo FJ, Rodriguez-Martin S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A et al. Use of renin-angiotensin-al-dosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study. Lancet. 2020;395(1):1705-14. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31030-8/ fulltext

Home